Several SLC45A3–ELK4 fusions have been reported; the primary form is a fusion of SLC45A3 exon 1 with the last four exons of ELK4. Interestingly, although SLC45A3–ELK4 functions as a fused lncRNA, its knockdown in cancer cells leads to reduction in cell proliferation, despite its unclear oncogenic roles [36]. The gene discussed is SLC45A3; the disease is cancer.